Treat 4 Ramadan trial: a randomised control trial comparing liraglutide vs a sulphonylurea as add-on to metformin in patients with established type 2 diabetes

被引：0
|
作者：
Brady, E. M. [1 ]
Davies, M. J. [2 ]
Gray, L. J. [3 ]
Saeed, M. A. [4 ]
Hanif, W. [4 ]
Khunti, K. [2 ]
机构：
[1] Univ Leicester, Leicester Diabet Ctr, Leicester, Leics, England
[2] Univ Leicester, Diabet Res Unit, Leicester, Leics, England
[3] Univ Leicester, Leicester, Leics, England
[4] Univ Hosp Birmingham, Leicester, Leics, England
来源：
DIABETOLOGIA | 2013年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
928
引用
收藏
页码：S371 / S371
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of lixisenatide vs sulphonylurea added to basal insulin in Indian patients with type 2 diabetes who fast during Ramadan in the LixiRam randomised trial
    Sahay, R.
    Hafidh, K.
    Djaballah, K.
    Azar, S.
    Shehadeh, N.
    Hanif, W.
    Hassanein, M. M.
    DIABETOLOGIA, 2019, 62 : S372 - S373
  • [22] Dapagliflozin plus Saxagliptin Add-On vs. Glimepiride Add-On to Metformin in Patients with Poorly Controlled Type 2 Diabetes
    Frias, Juan P.
    Gonzalez-Galvez, Guillermo
    Johnsson, Eva K.
    Maaske, Jill
    Peters, Anne
    DIABETES, 2018, 67
  • [23] Sitagliptin Add-On to Metformin plus Sulphonylurea Combination Therapy: The Efficacy of Triple Therapy on Glycemic Control in Type 2 Diabetes
    Sargin, Mehmet
    Tekin, Sakin
    Can, Ozgur
    Kisioglu, Savas Volkan
    Tekin, Buket Vatansever
    Orbay, Ekrem
    Tekce, Mustafa
    Aliustaoglu, Mehmet
    DIABETES, 2013, 62 : A669 - A670
  • [24] Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial
    Sartore, Giovanni
    Ragazzi, Eugenio
    Antonello, Giulia
    Cosma, Chiara
    Lapolla, Annunziata
    NUTRIENTS, 2021, 13 (07)
  • [25] Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial
    Nauck, Michael
    Rizzo, Manfredi
    Johnson, Andrew
    Bosch-Traberg, Heidrun
    Madsen, Jesper
    Cariou, Bertrand
    DIABETES CARE, 2016, 39 (09) : 1501 - 1509
  • [26] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN TYPE 2 DIABETES PATIENTS IN CHINA
    Gao, Lan
    Zhao, Fei-Li
    Li, Shu-Chuen
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2012, 28 (04) : 436 - 444
  • [27] COST-UTILITY ANALYSIS OF LIRAGLUTIDE VERSUS GLIMEPIRIDE AS ADD-ON TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
    Gao, L.
    Li, S. C.
    VALUE IN HEALTH, 2012, 15 (07) : A663 - A663
  • [28] Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin
    Hermansen, Kjeld
    Kolotkin, Ronette L.
    Hammer, Mette
    Zdravkovic, Milan
    Matthews, David
    PRIMARY CARE DIABETES, 2010, 4 (02) : 113 - 117
  • [29] COST-EFFECTIVENESS OF SITAGLIPTIN COMPARED TO SULPHONYLUREA AS AN ADD-ON TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES IN GREECE
    Athanasakis, K.
    Zhuo, J.
    Chen, J.
    Boubouchairopoulou, N.
    Tarantilis, F.
    Papageorgiou, M.
    Retsa, P.
    Brandtmuller, A.
    Tunceli, K.
    Karokis, A.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2015, 18 (07) : A608 - A608
  • [30] Effects of Pioglitazone Add-On to Gliclazide and Metformin on Glycemic Control in Patients with Type 2 Diabetes
    Al-Azzam, Sayer I.
    AlOmari, Mousa
    Khader, Yousef S.
    AlMahasneh, Fatimah A.
    Muflih, Suhaib M.
    Altawalbeh, Shoroq
    ENDOCRINE RESEARCH, 2012, 37 (01) : 7 - 11
12345